AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar pchop123 (71.80) Submitted: 2/9/2012 4:19:27 PM : Underperform Start Price: $1.19 AVII Score: +11.83

Profit is the impossible dream here

Report this Post Reply

Featured Broker Partners


Advertisement